STOCK TITAN

Femasys Inc. (FEMY) executive buys stock and gets milestone warrants

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Femasys Inc. executive Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, acquired equity-linked interests on August 7, 2026. He purchased 3,125 shares of common stock at $3.20 per share for an aggregate $10,000, and received two warrants for 3,125 shares each with a $2.95 exercise price, one immediately exercisable (subject to Nasdaq-related limitations) and one tied to future revenue and stock-price milestones.

Positive

  • None.

Negative

  • None.
Insider Mifek Jeffrey Gerald
Role Chief Clinical-Medical Affairs
Bought 3,125 shs ($10K)
Type Security Shares Price Value
Grant/Award Common Stock Purchase Warrant F2, F4, F3 3,125 -- --
Grant/Award Common Stock Purchase Warrant (Milestone) F2, F4, F5, F3 3,125 -- --
Purchase Common Stock F1 3,125 $3.20 $10K
Holdings After Transaction: Common Stock Purchase Warrant — 3,125 shares (Direct); Common Stock Purchase Warrant (Milestone) — 3,125 shares (Direct); Common Stock — 3,125 shares (Direct)
Footnotes (5)
  1. F1. The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.
  2. F2. Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.
  3. F3. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.
  4. F4. The reported securities were purchased by the reporting person for an aggregate amount of $10,000.
  5. F5. The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.
Common shares purchased 3,125 shares Common Stock purchased on August 7, 2026
Purchase price per share $3.20 per share Price paid for common stock under Securities Purchase Agreement
Aggregate purchase amount $10,000 Total paid by reporting person for the reported securities
Regular warrant size 3,125 shares Common Stock Purchase Warrant underlying common shares
Milestone warrant size 3,125 shares Common Stock Purchase Warrant (Milestone) underlying common shares
Warrant exercise price $2.95 per share Exercise price for both reported common stock purchase warrants
Revenue milestone $1,500,000 U.S. revenue for any fiscal quarter required for Milestone Date
Regular warrant expiration 2029-08-10 Expiration date of the immediately exercisable common warrant
Common Stock Purchase Warrant financial
"Holder may, at its option, exercise the Common Warrant, subject to the terms"
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
Milestone Date financial
"The Common Warrant (Milestone) is exercisable only from and after the Milestone Date"
volume-weighted average price financial
"the volume-weighted average price of the Common Stock has satisfied certain price conditions"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
Nasdaq Capital Market financial
"subject to certain limitations, in accordance with rules of the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
registration statement regulatory
"three years after the effective date of a registration statement registering the resale"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did FEMY executive Jeffrey Gerald Mifek buy on August 7, 2026?

Jeffrey Gerald Mifek bought 3,125 shares of Femasys common stock at $3.20 per share. According to the disclosure, the shares were purchased for an aggregate $10,000 under a Securities Purchase Agreement dated August 7, 2026.

What warrants did the FEMY executive receive in this Form 4 filing?

Mifek received two Common Stock Purchase Warrants, each for 3,125 shares of Femasys common stock at an exercise price of $2.95 per share. One is a regular warrant and the other is a Milestone warrant with additional performance conditions.

When can the milestone warrant reported for FEMY be exercised?

The Milestone warrant is exercisable only from and after the Milestone Date. That date requires Femasys to report $1,500,000 U.S. revenue for any fiscal quarter and for its stock’s volume-weighted average price to meet specified conditions.

Are there limits on exercising the FEMY common stock warrants?

Yes. The company states the holder’s ability to exercise the warrant for common shares is subject to limitations under Nasdaq Capital Market rules. The exercise price of $2.95 per share is also subject to adjustment for stock splits and similar corporate actions.

What is the aggregate amount paid by the FEMY insider in this transaction?

The insider paid an aggregate of $10,000 for the securities. This total covers the purchase of 3,125 common shares at $3.20 per share pursuant to a Securities Purchase Agreement dated August 7, 2026.

Is the FEMY Form 4 transaction under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmative, and no footnote describes a trading plan. The transactions are therefore reported without being identified as made under a pre-arranged 10b5-1 plan.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mifek Jeffrey Gerald

(Last)(First)(Middle)
C/O FEMASYS INC.
3950 JOHNS CREEK COURT, SUITE 100

(Street)
SUWANEE GEORGIA 30024

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
FEMASYS INC [ FEMY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Clinical-Medical Affairs
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/07/2026P3,125A$3.2(1)3,125D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Common Stock Purchase Warrant$2.95(2)08/07/2026A3,12508/10/202608/10/2029Common stock, par value $0.001 per share3,125(3)(4)3,125D
Common Stock Purchase Warrant (Milestone)$2.95(2)08/07/2026A3,12508/10/2027(5) (5)Common stock, par value $0.001 per share3,125(3)(4)3,125D
Explanation of Responses:
1. The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.
2. Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.
3. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.
4. The reported securities were purchased by the reporting person for an aggregate amount of $10,000.
5. The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.
/s/ Kathy Lee-Sepsick, Attorney-in-fact08/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)